Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Access to Medical Treatment Act

This article was originally published in The Tan Sheet

Executive Summary

Access to Medical Treatment Act: Is expected to be introduced the week of June 26 by Rep. Peter DeFazio (D-Ore.). The bill, which was introduced last year by DeFazio as HR 4696 and by Sen. Tom Daschle (D-S.D.) as S 2140, broadens access to unapproved medical treatments provided they are not harmful. The 1995 version has been amended to address concerns raised by the dietary supplement industry that language in the bill could allow a supplement to be deemed "dangerous" if given in conjunction with a harmful therapy ("The Tan Sheet" March 20, p. 14). The bill is understood to contain a provision stating that the act will not conflict with the Dietary Supplement Health & Education Act. DeFazio is considering a hearing on the issue...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS083958

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel